

DYNAVAX TECHNOLOGIES CORP

Form 424B7

August 17, 2007

**Prospectus Supplement No. 1**

Filed Pursuant to  
Rule 424(b)(7)  
File No. 333-134688

**Dynavax Technologies Corporation**  
**2,000,000 Shares**  
**Common Stock**

This prospectus supplement supplements the prospectus contained in the Registration Statement, dated June 2, 2006, relating to the offering and sale by selling stockholder of up to 2,000,000 shares of our common stock. This prospectus supplement should be read in conjunction with the prospectus, and is qualified by reference to the prospectus, except to the extent that the information presented herein supersedes the information contained in the prospectus. The term selling stockholders as used in the prospectus shall be deemed to include the selling stockholders identified in the table below. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any amendments or supplements thereto.

The shares of common stock offered under the prospectus and this prospectus supplement by the selling stockholders were issued pursuant to a warrant dated April 18, 2006, issued by Dynavax to Symphony Dynamo Holdings LLC. We are not selling any securities under the prospectus or its supplements and will not receive any of the proceeds from the sale of shares by the selling stockholders.

***Investing in our common stock involves risks and uncertainties. You should review carefully the risks and uncertainties described under the heading Risk Factors beginning on page 2 of the prospectus and under similar headings in each document that is incorporated in the prospectus by reference.***

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the prospectus or this supplement is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus supplement is August 15, 2007.

---

The table appearing on page 14 of the prospectus under the caption **Selling Stockholders** is supplemented and amended to include the following stockholders:

<b>Name of Security Holders</b>	<b>Number of Shares Owned Prior to Offering</b>	<b>Maximum Number of Shares to be sold Pursuant to this Prospectus</b>	<b>Shares of Common Stock Beneficially Owned After Offering</b>	<b>Percent</b>
Symphony Capital Partners, L.P.(1)	1,217,040	1,217,040	0	
Symphony Strategic Partners, LLC(1)	66,160	66,160	0	
RRD International, LLC 7361 Calhoun Place, Suite 325 Rockville, MD 20855-2765	40,000	40,000	0	
Howard Hughes Medical Institute 4000 Jones Bridge Road Chevy Chase, MD 20815	188,000	188,000	0	
Stormlaunch & Co. for the benefit of Morgan Stanley Private Markets Fund III LP (2)	150,400	150,400	0	
Mellon Bank, N.A., solely in its capacity as Trustee for the Weyerhaeuser Company Master Retirement Trust (2)	94,000	94,000	0	
Sailorshell & Co., for the benefit of Morgan Stanley AIP Global Diversified Fund LP (2)	56,400	56,400	0	
Sailorpass & Co. for the benefit of Morgan Stanley Private Markets Fund I LP (2)	37,600	37,600	0	
Factory Mutual Insurance Company(2)	15,040	15,040	0	
Nuclear Electric Insurance Ltd. (2)	15,040	15,040	0	
Stormbay & Co. for the benefit of Vijverpoort Huizen C.V. (2)	7,520	7,520	0	
UBS O Connor LLC for the benefit of O Connor PIPES Corporate Strategies Master Limited 1 North Wacker Drive Chicago, IL 60606	37,600	37,600	0	

WHI Morula Fund 191 N. Wacker Drive, Ste. 1500 Chicago, IL 60606	37,600	37,600	0
Sailorpier & Co. for the benefit of Aurora Cayman Limited (2)	33,088	33,088	0
Stormstar & Co. for the benefit of Morgan Stanley Private Markets Fund Employee Investors III LP (2)	4,512	4,512	0
Total:	2,000,000	2,000,000	0

(1) Symphony  
Capital Partners,  
L.P. is  
controlled by  
Symphony  
Capital GP,  
L.P., it general  
partner, which is  
in turn  
controlled by  
Symphony GP,  
LLC, its general  
partner.  
Symphony  
Capital LLC, as  
the investment  
advisor of  
Symphony  
Capital Partners,  
L.P., maintains  
voting  
discretion and  
investment  
control over  
these shares.  
The address for  
each is 875  
Third Avenue,  
18<sup>th</sup> Floor, New  
York, NY  
10022.

(2) Address is c/o  
Morgan Stanley  
Investment  
Management,  
Inc., One Tower

Bridge, 100  
Front Street,  
Suite 1100,  
West  
Conshohocken,  
PA 19428-2881,  
Attention:  
Matthew Allen.